Bicycle Therapeutics (NASDAQ:BCYC) Given New $7.00 Price Target at Royal Bank Of Canada

Bicycle Therapeutics (NASDAQ:BCYC) had its price target cut by Royal Bank Of Canada from $11.00 to $7.00 in a research report released on Wednesday morning,Benzinga reports. They currently have a sector perform rating on the stock.

A number of other equities research analysts also recently weighed in on BCYC. Morgan Stanley reissued a “sell” rating and set a $13.00 target price on shares of Bicycle Therapeutics in a report on Tuesday. Weiss Ratings restated a “sell (e+)” rating on shares of Bicycle Therapeutics in a research note on Monday, December 22nd. Citizens Jmp lowered their price target on shares of Bicycle Therapeutics from $12.00 to $8.00 and set a “market outperform” rating on the stock in a research report on Wednesday. Jefferies Financial Group upgraded shares of Bicycle Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 17th. Finally, Truist Financial set a $8.00 target price on shares of Bicycle Therapeutics in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $14.50.

Bicycle Therapeutics Trading Down 7.3%

Bicycle Therapeutics stock opened at $4.70 on Wednesday. The company has a market capitalization of $326.04 million, a price-to-earnings ratio of -1.49 and a beta of 1.65. Bicycle Therapeutics has a 12 month low of $4.59 and a 12 month high of $9.94. The stock’s 50 day moving average is $5.87 and its 200-day moving average is $6.79.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings results on Tuesday, March 17th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.71. Bicycle Therapeutics had a negative return on equity of 32.40% and a negative net margin of 301.66%.The business had revenue of $47.96 million during the quarter, compared to the consensus estimate of $7.08 million. As a group, equities research analysts predict that Bicycle Therapeutics will post -3.06 earnings per share for the current fiscal year.

Insider Buying and Selling at Bicycle Therapeutics

In related news, CEO Kevin Lee sold 10,989 shares of the business’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $6.46, for a total value of $70,988.94. Following the completion of the transaction, the chief executive officer owned 618,996 shares of the company’s stock, valued at $3,998,714.16. The trade was a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Alethia Young sold 4,334 shares of the company’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $6.49, for a total transaction of $28,127.66. Following the sale, the chief financial officer directly owned 87,081 shares of the company’s stock, valued at $565,155.69. This represents a 4.74% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 38,029 shares of company stock worth $251,966. 22.90% of the stock is currently owned by insiders.

Institutional Trading of Bicycle Therapeutics

Several large investors have recently made changes to their positions in the company. Assetmark Inc. raised its position in Bicycle Therapeutics by 74.9% during the third quarter. Assetmark Inc. now owns 3,625 shares of the company’s stock valued at $28,000 after purchasing an additional 1,552 shares in the last quarter. Clearstead Advisors LLC boosted its holdings in shares of Bicycle Therapeutics by 234.2% in the 4th quarter. Clearstead Advisors LLC now owns 4,655 shares of the company’s stock valued at $33,000 after purchasing an additional 3,262 shares in the last quarter. Brooklyn Investment Group acquired a new stake in shares of Bicycle Therapeutics in the 4th quarter valued at $69,000. Ausdal Financial Partners Inc. bought a new position in shares of Bicycle Therapeutics in the 2nd quarter valued at $70,000. Finally, Pinnacle Wealth Management Advisory Group LLC bought a new position in shares of Bicycle Therapeutics in the 4th quarter valued at $71,000. Institutional investors and hedge funds own 86.15% of the company’s stock.

Bicycle Therapeutics News Summary

Here are the key news stories impacting Bicycle Therapeutics this week:

• Positive Sentiment: Q4 results materially beat expectations — Bicycle reported EPS of ($0.29) vs. consensus ($1.00) and revenue of $47.95M vs. $7.08M, a large topline surprise that supports the company’s commercial progress and clinical outlook. Read More.
• Neutral Sentiment: Short‑interest reports show a “large increase” flagged for March but list zero shares and NaN changes; the short‑interest ratio is reported as 0.0 days — this appears to be a reporting/data anomaly and is unlikely to be a meaningful driver while figures remain inconsistent.
• Negative Sentiment: Oppenheimer cut its price target from $44 to $36 but kept an “outperform” rating — a notable reduction in upside that can weigh on sentiment. Read More.
• Negative Sentiment: Royal Bank of Canada lowered its target from $11 to $7 and moved to “sector perform” — another downward revision that reduces analyst‑implied valuation. Read More.
• Negative Sentiment: Citizens Jmp trimmed its target from $12 to $8 while maintaining “market outperform” — a cut that may temper near‑term enthusiasm. Read More.
• Negative Sentiment: Needham lowered its target from $24 to $15 but kept a “buy” rating — another sizable reduction in analyst upside that could pressure the stock despite the buy rating. Read More.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.